Yale Researchers Present Results of Phase II Phenoxodiol Clinical Trial in Prostate Cancer Patients at ASCO 2009 Genitourinary Cancers Symposium
Marshall Edwards, Inc. (NASDAQ: MSHL) is planning to release preliminary results from a Phase II clinical trial of oral phenoxodiol in patients with early and advanced stage prostate cancer. The results will be presented by the Yale researchers, who were responsible for the study, at the ASCO Genitourinary Cancers Symposium in Orlando, Florida; February 26-28, [...]